Description

SBICAP Securities Limited has listed new Commercial Paper worth Rs. 400 crore (8000 units of Rs. 5 lakhs each) on BSE Debt segment with maturity on March 10, 2026.

Summary

SBICAP Securities Limited has listed new Commercial Paper on BSE Debt segment on December 10, 2025. The issue comprises 8000 units of Rs. 5,00,000 each (total Rs. 400 crore) issued on private placement basis. The paper carries CRISIL A1+ and ICRA A1+ ratings with a tenure of 91 days from allotment to redemption.

Key Points

  • Total issue size: Rs. 400 crore (8000 units)
  • Face value per unit: Rs. 5,00,000
  • Issue price: Rs. 4,91,954 (discount of Rs. 8,046 per unit)
  • Credit ratings: CRISIL A1+ and ICRA A1+
  • Scrip Code: 730726
  • Scrip ID: SSL91225
  • ISIN: INE212K14CY1
  • Market lot: 1 unit
  • Trading in dematerialized form only
  • Standard denomination: Rs. 5 lakhs and multiples thereof
  • Tick size: 1 paise
  • Issuing and Paying Agent: State Bank of India

Regulatory Changes

No regulatory changes announced in this circular.

Compliance Requirements

  • Trading members must trade these securities only in dematerialized form
  • Trading must be conducted in standard denomination of Rs. 5 lakhs and multiples thereof
  • Members should use the specified ISIN number INE212K14CY1 for all transactions

Important Dates

  • Notice date: December 10, 2025
  • Actual/Deemed date of allotment: December 9, 2025
  • Listing date: December 10, 2025
  • Redemption date: March 10, 2026
  • Tenure: 91 days

Impact Assessment

This is a routine commercial paper listing with minimal market impact. The instrument is meant for institutional investors and does not affect retail equity markets. The high credit ratings (A1+ from both CRISIL and ICRA) indicate strong creditworthiness. Trading members dealing in debt instruments should note the new scrip for client portfolios. Contact debt department at BSE (22728352/8597/8995/5753/8915) for clarifications.

Impact Justification

Routine commercial paper listing for institutional debt instrument with no impact on equity markets or retail investors